糖心vlog

This Viewpoint clarifies 3 treatment options for treating patients with elevated cholesterol levels by discussing patient goals, encouraging lifestyle changes, and using lipid-lowering medication.

This Viewpoint discusses variances in cardiovascular prevention guidelines from the United States, Europe, and Canada and the debate surrounding low-density lipoprotein levels as the primary focus.

In this Viewpoint, FDA Commissioner Scott Gottlieb and CDER Director Janet Woodcock discuss how the FDA weighs the risks and benefits of opioids and integrates public health and clinical perspectives into decisions about opioid approval, marketing, restrictions, and labeling.

This Viewpoint describes the National Academies of Sciences, Engineering, and Medicine鈥檚 new report on the harms associated with opioid misuse and the effects of strategies to reduce those harms, and discusses the importance of balancing patients鈥� pain management and addressing the current opioid epidemic.

This Viewpoint from the acting director of the CDC and coauthors reports data on opioid prescribing and related misuse and overdose-related deaths for the period 2006-2015 in the United States.